Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187133 | 0.80 | KCNJ1 (0.51) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL4548443 | 0.70 | CRBN (0.41) | ALDH1A1IDH1IDH2 | |
| SCHEMBL16906442 | 0.68 | KCNJ1 (1.00) | KCNJ1ALDH1A1TDP1MAPT | |
| SCHEMBL10187149 | 0.66 | HCAR2 (0.38) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL12824361 | 0.65 | ALDH1A1 (0.96) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL360323 | 0.64 | — | — | |
| SCHEMBL430996 | 0.63 | KCNJ1 (0.47) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL13711958 | 0.63 | ALDH1A1 (1.00) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL12515889 | 0.63 | ALDH1A1 (1.00) | KCNJ1ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL17099921 | 0.63 | ALDH1A1 (0.48) | KCNJ1ALDH1A1TDP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | KCNJ1 1514/4885ALDH1A1 1106/4885TDP1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.